secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENERON PHARMACEUTICALS, INC. (REGN)
CIK:        0000872589
Form:       8-K
Filed at:   2025-04-29T23:59:59+00:00
Accession:  0001804220-25-000020
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Regeneron Q1 revenue down 4%, non-GAAP EPS falls 14%; lowers gross margin guidance
--------------------------------------------------------------------------------

- Q1 2025 revenue $3.03B (-4% YoY); GAAP EPS $7.27 (+16%), non-GAAP EPS $8.22 (-14%).
- Dupixent global net sales (Sanofi) up 19% to $3.67B; EYLEA HD US up 54% but total EYLEA franchise down 26% to $1.04B.
- FDA issued CRL for EYLEA HD pre-filled syringe (non-safety, third-party supplier issue) and separate CRL denying extended dosing beyond every 16 weeks.
- Lowers 2025 GAAP gross margin guidance to 83%-84%, non-GAAP to 86%-87% (prior 84%-85% and 87%-88%).
- Settled EYLEA biosimilar litigation with Biocon; launch precluded until H2 2026; entered 10-year manufacturing agreement with Fujifilm.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872589/000180422025000020/0001804220-25-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872589/000180422025000020/regn-20250429.htm
  HTML page:      https://secwatch.observer/filing/0001804220-25-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer